References
US Food and Drug Administration. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. Code of Federal Regulations.21CFR314 §510.
Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials. Alzheimer’s and Dementia. 2006;2:263–271.
Bradley KM, Bydder GM, Budge MM, Hajnal JV, White SJ, Ripley BD, et al. Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer’s disease. Br J Radiol. 2002;75:506–513.
Jobst KA, Smith AD, Barker CS, Wear A, King EM, Smith A, et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1992;55:190–194.
Brown DRP, Hunter R, Wyper DJ, Patterson J, Kelly RC, Montaldi D, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer’s disease: A SPECT blood flow study. J Psychiatr Res. 1996;30:109–126.
Venneri A, Shanks MF. Charting patterns of progression in treated and untreated patients with Alzheimer’s disease using SPECT. Neurobiol Aging. 2002;23:S125–S126.
Cabranes JA, de Juan R, Encinas M, Marcos A, Gil P, Fern C, et al. Relevance of functional neuroimaging in the progression of mild cognitive impairment. Neurol Res. 2004;26:496–501.
Caroli A, Testa C, Geroldi C, Nobili F, Barnden LR, Guerra UP, et al. Cerebral perfusion correlates of conversion to Alzheimer’s disease in amnestic mild cognitive impairment. J Neurol 2007;254:1698–1707.
Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment — Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology. 2003;60:1374–1377.
Encinas M, Juan R, Marcos A, Gil P, Barabash A, Fernández C, et al. Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer’s disease. Eur J Nuc Med Mol Imaging. 2003;30:1473–1480.
Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–1500.
Katsuno T, Morishima-Kawashima M, Saito Y, Yamanouchi H, Ishiura S, Murayama S, et al. Independent accumulations of tau and amyloid -protein in the human entorhinal cortex. Neurology. 2005;64:687–692.
Mani RB. The evaluation of disease modifying therapies in Alzheimer’s disease: a regulatory viewpoint. Stat Med. 2004;23:305–314.
Aisen PS. Commentary on “Challenges to demonstrating disease-modifying effects in Alzheimer’s disease clinical trials.”. Alzheimer’s and Dementia. 2006;2:272–274.
Matsuda H, Kitayama N, Ohnishi T, Asada T, Nakano S, Sakamoto S, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer’s disease. J Nuc Med. 2002;43:304–311.
Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills R, et al. Staging of cytoskeletal and -amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer’s disease. Am J Pathol. 2000;157:623–636.
Garcia-Sierra F, Hauw JJ, Duyckaerts C, Wischik CM, Luna-Muñoz J, Mena R. The extent of neurofibrillary pathology in perforant pathway neurons is the key determinant of dementia in the very old. Acta Neuropathol. 2000;100:29–35.
Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746.
Jagust W, Thisted R, Devous MD, Sr., Van Heertum R, Mayberg H, Jobst K, et al. SPECT perfusion imaging in the diagnosis of Alzheimer’s disease. A clinicopathologic study. Neurology. 2001;56:950–956.
Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Zscore imaging system for multicenter brain perfusion single-photon emission tomography. Am J Neuroradiol. 2007;28:731–736.
El Fakhri G, Kijewski MF, Albert MS, Johnson KA, Moore SC. Quantitative SPECT leads to improved performance in discrimination tasks related to prodromal Alzheimer’s disease. J Nuc Med. 2004;45:2026–2031.
Imabayashi E, Matsuda H, Asada T, Ohnishi T, Sakamoto S, Nakano S, et al. Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer’s disease from controls using brain perfusion SPECT. J Nuc Med. 2004;45:1450–1457.
Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe.K. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dementia Geriat Cognit Disord. 2005;20:25–30.
Hanyu H, Shimizu S, Hirao K, Kanetaka H, Sakurai H, Iwamoto T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using minimental state examination and brain perfusion SPECT. J Neurol Sci. 2006;250:97–102.
Nagao M, Sugawara Y, Ikeda M, Fukuhara R, Hokoishi K, Murase K, et al. Heterogeneity of cerebral blood flow in frontotemporal lobar degeneration and Alzheimer’s disease. Eur J Nuc Med Mol Imaging. 2004;31:162–168.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wischik, C., Staff, R. Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy. J Nutr Health Aging 13, 367–369 (2009). https://doi.org/10.1007/s12603-009-0046-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-009-0046-5